- Nikki Blackwell1,
- L Bangham1,
- M Hughes1,
- D Melzack1,
- Ivan Trotman1
- Unknown1
1993
ExcerptNot all pain due to advanced malignant disease is opioid responsive. In addition the use of opioids at doses high enough to provide adequate analgesia may sometimes be limited by adverse effects, such as confusion, hallucinations, vomiting and profound constipation.
We have previously described the successful use of ketorolac, a new injectable non-steriodal anti- inflammatory drug, administered by continuos sub-cutaneous infusion in seven patients with opioid analgesia. This was considered to be because of opioid unresponsiveness (n = 1), opioid related adverse effects (n = 1) or both (n = 5). All of. these patients become symptom free with a sub-cutanous ketorolac infusion, four had their opioids discontinued and three had their daily opioid requirement reduced substantially.
We have subsequently broadened our experience with ketorolac and we use it both by sub- cutaneous infusion and in its oral form as first-line treatment for certain symptoms caused by advanced malignant disease. We present a further 40 patients in whom excellent symptom control was achieved using this drug - particularly patients with pain due to bony metastases, hypertrophic pulmonary osteoarthropathy and radicular pain.
We believe therefore that ketorolac is an important advance in symptom management, particularly because of its ease of administration by conventional sub-cutaneous syringe driver.
Further research should concentrate on its mode of action; whilst it has been shown not to act at opioid receptors we believe that it may be effective by different mechanisms than those of conventional non-steriodal anti-inflammatory drugs.